ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Advanced Search

Characteristics and Outcomes of Resistant Cytomegalovirus (CMV) Disease in Solid Organ Transplant (SOT) Patients

P. Chong, P. Deziel, R. Razonable

Mayo Clinic, Rocheste

Meeting: 2013 American Transplant Congress

Abstract number: A577

Related Abstracts
  • Safety and Outcome of Ganciclovir-Resistant CMV Treated With Foscarnet: A Single Center Retrospective Study
  • Risk Factors of Post-Transplant High-Grade CMV Reactivation in CMV-Seropositive Patients in the Modern Immunosuppressive Era

Objective: We assessed the characteristics and outcomes of genotype-proven resistant CMV after SOT.

Methods : The SOT database was reviewed during 2001-2012 to identify patients with genotype-proven resistant CMV.

Results: Nine of 3444 (0.26%) patients developed genotype-proven resistant CMV, including 5 KT, 2 PAK, 1 LT and 1 lung. All were CMV D+/R-. Most (n=7) had tissue-invasive CMV disease. One patient died, and two had drug-induced graft loss. Most (n=8) had UL97, one had isolated UL54, and two developed UL54 mutations during treatment.

Table 1:

Table 1
Patient Age/Sex/Transplant type CMV disease/Initial CMV loada/Mutation Onsetb Duration of (V)GCV exposurec Initial Therapy Definitive Therapy Outcome
1 64/F/KT GI disease;474,000;UL97 (NR) 132 132 VGCV (6w) FOS+CMVIG Died;Graft loss (FOS)
2 59/M/KT GI disease;101,000;UL97 (NR) 122 192 VGCV (4w) then MT FOS+CMVIG Alive;Interstitial nephritis (FOS)
3 54/M/PAK CMV Syndrome;5211;UL54 (NR) 150 300 VGCV (16w) CDV+CMVIG Alive;Graft loss (FOS/CDV)
4 35/M/PAK GI disease;263,000;UL97 (NR) 173 270 IV GCV (1w) then VGCV (7w) then MT FOS Alive;Pancreas rejection (IS reduction)
5 52/M/LT GI disease;50,500;UL97 (A594V) 23 N/Ad IV GCV (2w) then VGCV (2w) then MT 1.IV GCV 2.FOS 3.VGCV Alive;Elev cre (FOS)
6 45/F/KT GI disease;27,700;UL97 (C603W) 137 137 IV GCV (2w)+CMVIG FOS+CMVIG Alive;Rash (FOS)
7 57/M/KT CMV Syndrome;3000;UL97 (A594V) 88 88 VGCV (7w) then MT (2w) 1.IV GCV 2.FOS Alive;Elev cre (FOS)
8 65/M/KT GI disease;5490;UL97 (L595S) then UL54(A987G/A) 358 93 IV GCV (6w) then MT 1.IV GCV+CMVIG 2.VGCV 3.High dose IV GCV+CMVIG 4.CMVIG Alive
9 43/M/Lung Tx Multiorgan;794,000;UL97 (C603W) the UL54(T503T/I) 332 332 IV GCV (1w) 1.FOS 2.CDV+CMVIG 3.FOS+CMVIG 4.Intravitreal FOS Alive;Encephalopathy (FOS). Elev cre (CDV)
F, female; M, male; CMVIG, CMV immunoglobulin; GCV, ganciclovir; VGCV, valganciclovir; KT, kidney transplant; GI, gastrointestinal; PAK, pancreas after kidney transplant; LT, liver transplant; VL, viral load; NR, specific mutation not reported; IS, immunosuppression; MT, maintenance therapy. aCMV load in copies/milliliter of blood at diagnosis of CMV disease. bOnset of disease in days from time of last transplant. cDuration of VGCV exposure in days at the time when resistance was suspected. dN/A : Did not receive prophylaxis. FOS, foscarnet. CDV, cidofovir. Cre, creatinine

Conclusions: Drug-resistant CMV is an uncommon but potentially fatal infection. Treatment-related graft loss is common. Resistance may develop during treatment.

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Chong P, Deziel P, Razonable R. Characteristics and Outcomes of Resistant Cytomegalovirus (CMV) Disease in Solid Organ Transplant (SOT) Patients [abstract]. Am J Transplant. 2013; 13 (suppl 5). https://atcmeetingabstracts.com/abstract/characteristics-and-outcomes-of-resistant-cytomegalovirus-cmv-disease-in-solid-organ-transplant-sot-patients/. Accessed April 19, 2021.

« Back to 2013 American Transplant Congress

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Penis Transplantation: First U.S. Experience.
  • Kidney Dialysis after Heart Transplantation: The Short and Long Term Outcomes
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Penis Transplantation: First U.S. Experience.
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Live Related Kidney Transplant Experience in Abuja, Nigeria – First Eight Cases Ever.
  • Home
  • Search
  • Penis Transplantation: First U.S. Experience.
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2021 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.